Literature DB >> 11342435

Effect of the Pl(A2) alloantigen on the function of beta(3)-integrins in platelets.

J S Bennett1, F Catella-Lawson, A R Rut, G Vilaire, W Qi, S C Kapoor, S Murphy, G A FitzGerald.   

Abstract

The polymorphism responsible for the Pl(A2) alloantigen on the beta(3)-component of beta(3)-containing integrins is reported to be a risk factor for coronary thrombosis. This study examined the effect of Pl(A2) on the function of beta(3)-integrins using platelets from subjects homozygous and heterozygous for Pl(A1) and Pl(A2). There was overlap in the distribution of the dissociation constant (K(d)) and maximum fibrinogen binding (B(max)) values for fibrinogen binding to alpha(IIb)beta(3) on platelets from Pl(A1) and Pl(A2) homozygotes and Pl(A1)/Pl(A2) heterozygotes. However, whereas there was no statistical difference in these values for the Pl(A1) homozygotes and Pl(A2) heterozygotes, the K(d) for the Pl(A2) homozygotes was significantly lower than that for the Pl(A1)/Pl(A2) heterozygotes, but was not statistically different from that for the Pl(A1) homozygotes. No differences were detected in ADP sensitivity between platelets from Pl(A1) homozygotes and Pl(A1)/Pl(A2) heterozygotes, in the IC(50) for RGDS inhibition of fibrinogen binding to alpha(IIb)beta(3), in the alpha(v)beta(3)-mediated adhesion of platelets to osteopontin and vitronectin, and in the phorbol ester-stimulated adhesion to fibrinogen of B lymphocytes expressing alpha(IIb)beta(3) containing either the Pl(A1) or the Pl(A2) polymorphism. Finally, no differential effects of Pl(A2) on turbidometric platelet aggregation, platelet secretion, or platelet thrombus formation were found as measured in the PFA-100. Because no differences were detected in the ability of beta(3)-integrins to interact with ligands based on the presence or absence of the Pl(A2) polymorphism, the results suggest that factors unrelated to beta(3)-integrin function may account for the reported association of the Pl(A2) allele with coronary thrombosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11342435     DOI: 10.1182/blood.v97.10.3093

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  17 in total

Review 1.  Comparative pharmacology of GP IIb/IIIa antagonists.

Authors:  Karsten Schrör; Artur-Aron Weber
Journal:  J Thromb Thrombolysis       Date:  2003-04       Impact factor: 2.300

Review 2.  The genetics of normal platelet reactivity.

Authors:  Thomas J Kunicki; Diane J Nugent
Journal:  Blood       Date:  2010-07-07       Impact factor: 22.113

3.  Integrin beta3 Leu33Pro polymorphism increases BRCA1-associated ovarian cancer risk.

Authors:  Anna Jakubowska; Jacek Gronwald; Janusz Menkiszak; Bohdan Górski; Tomasz Huzarski; Tomasz Byrski; Lutz Edler; Jan Lubinski; Rodney J Scott; Ute Hamann
Journal:  J Med Genet       Date:  2007-01-12       Impact factor: 6.318

4.  Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma.

Authors:  James R Cerhan; Stephen M Ansell; Zachary S Fredericksen; Neil E Kay; Mark Liebow; Timothy G Call; Ahmet Dogan; Julie M Cunningham; Alice H Wang; Wen Liu-Mares; William R Macon; Diane Jelinek; Thomas E Witzig; Thomas M Habermann; Susan L Slager
Journal:  Blood       Date:  2007-09-07       Impact factor: 22.113

Review 5.  The PlA1/A2 polymorphism of glycoprotein IIIa in relation to efficacy of antiplatelet drugs: a systematic review and meta-analysis.

Authors:  Christopher N Floyd; Albert Ferro
Journal:  Br J Clin Pharmacol       Date:  2014-03       Impact factor: 4.335

Review 6.  Platelets and depression in cardiovascular disease: A brief review of the current literature.

Authors:  Marlene S Williams
Journal:  World J Psychiatry       Date:  2012-12-22

Review 7.  MicroRNAs in lung cancer.

Authors:  Pooja Joshi; Justin Middleton; Young-Jun Jeon; Michela Garofalo
Journal:  World J Methodol       Date:  2014-06-26

Review 8.  Integrin αIIbβ3: from discovery to efficacious therapeutic target.

Authors:  Kamila Bledzka; Susan S Smyth; Edward F Plow
Journal:  Circ Res       Date:  2013-04-12       Impact factor: 17.367

9.  The Leu33Pro polymorphism in the ITGB3 gene does not modify BRCA1/2-associated breast or ovarian cancer risks: results from a multicenter study among 15,542 BRCA1 and BRCA2 mutation carriers.

Authors:  Anna Jakubowska; Dominik Rozkrut; Antonis Antoniou; Ute Hamann; Jan Lubinski
Journal:  Breast Cancer Res Treat       Date:  2009-10-30       Impact factor: 4.872

10.  Structure of an extended β3 integrin.

Authors:  Dongwen Zhou; Aye Myat Myat Thinn; Yan Zhao; Zhengli Wang; Jieqing Zhu
Journal:  Blood       Date:  2018-07-17       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.